Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 5/20 | 0.39 |
| ▸ | BDNF | P23560 | 3/20 | 0.37 |
| ▸ | PTN | P21246 | 2/20 | 0.37 |
| ▸ | MDK | P21741 | 2/20 | 0.37 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.32 |
| ▸ | M6PR | P20645 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14208603 | 0.89 | BDNF (0.38) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL14208602 | 0.89 | BDNF (0.38) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL14208595 | 0.85 | FGF2 (0.39) | FGF2AKT1 | |
| SCHEMBL14208598 | 0.82 | — | — | |
| SCHEMBL14208599 | 0.80 | BDNF (0.47) | F10BDNFPTNMDKFGF2 | |
| SCHEMBL14208664 | 0.79 | F10 (0.51) | F10BDNFPTNMDKSERPINC1 | |
| SCHEMBL14765307 | 0.73 | FGF2 (0.40) | FGF2AKT1 | |
| SCHEMBL14208633 | 0.73 | FGF2 (0.40) | FGF2AKT1 | |
| SCHEMBL14208645 | 0.73 | FGF2 (0.40) | FGF2AKT1 | |
| SCHEMBL14208600 | 0.73 | BDNF (0.51) | F10BDNFPTNMDKSERPINC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785416-B2 | Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases | BIOIBERICA, S.A. (ES) | 2014-07-22 | — | — | US | disclosed |
| US-20120309707-A1 | SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES | UNIVERSIDAD AUTONOMA DE MADRID (ES) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309707-A1 | SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES | GALC, SMN1; SMN2, SORD | F10 718/4885BDNF 46/4885PTN 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.